Efficacy of atezolizumab-bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent.

Ann Gastroenterol · 2024 · PMC11574153 · PMID 39568701

Europe PMC DOI

hedged sentence

0.2170

closest p · 4.3× alpha

0.2170

boldest claim

The sentences

did not reach statistical significanceP=0.217not close (p > 0.1)

Regarding treatment response, objective responses were more frequently observed in patients who were categorized as progressed BCLC-B stage (6/18, 33.3%) compared to BCLC-C staged patients (2/14, 14.3%), but these results did not reach statistical significance (P=0.217).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.